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Elafibranor Obeticholic acid (OCA)
Projected market entry: 2019
Mechanism of action Dual PPAR-α/δ agonist FXR ligand
Key clinical trial Phase II GOLDEN-505 study* Phase II FLINT study*
Study population N=274; adults with NASH (NAS≥3) without cirrhosis N=283; adults with NASH (NAS≥4) without cirrhosis†
Primary endpoint
Proportion of patients achieving resolution of NASH without worsening of 
fibrosis
Proportion of patients achieving ≥2 point reduction in NAS without 
worsening of fibrosis
Intervention Elafibranor 80 mg or 120 mg orally once daily or placebo for 52 weeks OCA 25 mg orally once daily or placebo for 72 weeks
Results
Resolution of NASH:  
19% for elafibranor vs 12% for placebo (P=0.045)
Improved liver histology:  
45% for OCA vs 21% for placebo (P=0.0002)
Key considerations for 
market uptake
• Positive effects on lipids and glucose
• Mild decrease in renal function
• Granted Fast Track designation
• FDA-approved for PBC
• Modest weight loss 
• Associated with pruritus and dyslipidemia
• Granted Breakthrough Therapy designation
• May resolve NASH, but ~80% of patients may not respond to treatment
• If untreated, NASH may progress until liver transplant is required
• No FDA-approved treatments indicated for NASH
• May improve liver histology
• Clinical trials evaluated surrogate endpoints
* Randomized, placebo-controlled          † Patients must have score of ≥1 in each component of NAS score          Abbreviations: FXR=farnesoid X nuclear receptor, NAS=NAFLD activity score, PBC=primary biliary cholangitis, PPAR=peroxisome proliferator-activated receptor
DISCUSSION
LIMITATIONS
• Clinical impact was based on Phase II trial data which assessed surrogate endpoints; 
Phase III trials are ongoing.
• Several assumptions were made in estimating budget impact:
 – Prevalence of disease in the Medicaid plan
 – Number of members diagnosed 
 – Number of members that would seek treatment
 – Cost of the agents
• The current analysis did not utilize medical claims data to determine the prevalence of 
disease in a specific population.
• Uptake of new therapies is difficult to assess due to the many variables that may influence it.
OBJECTIVE
To describe the pharmacy budget impact 
of elafibranor and obeticholic acid on a 
sample state Medicaid plan in the first 
year following their FDA-approval for 
the treatment of NASH.
METHODS
• A Medline search was conducted (timeframe: Jan. 1, 1995 to  
Oct. 30, 2017) to identify all published Phase II and Phase III clinical trials  
of elafibranor and obeticholic acid for NASH.
• Conference abstracts, manufacturer press-releases, and value assessments evaluating 
elafibranor and obeticholic acid for NASH during the same timeframe were also reviewed. 
• A clinical and economic assessment was performed to determine the budget impact.
 – The relative efficacy as well as the safety and tolerability of both medications were evaluated 
to predict their place in therapy. 
 – Key considerations for market uptake were identified to estimate unmanaged product uptake 
in the first year of market availability.
 – Available epidemiological data was extrapolated to estimate the proportion of members 
enrolled in a sample state Medicaid plan who would be treatment candidates. 
 – Annual drug cost was estimated using the wholesale acquisition cost of Ocaliva®  
(obeticholic acid).
Economic Assessment
• Estimated annual drug cost: $74,551
• Estimated prevalence of NASH: 3.5% to 5%1,2
• An estimated ~5% of patients who have NASH have been diagnosed.1,2
• Approximately 567,000 individuals in the U.S. may have the diagnosis and be eligible for 
treatment.2
• NASH is a chronic condition and treatment is continued until progression to cirrhosis  
(at which time a liver transplant may be required) or until resolution.1
Budget Impact
Medicaid plan of 100,000 covered lives:
RESULTS
Clinical Assessment        
CONCLUSIONS
• New agents for the treatment of NASH are likely to have a significant impact on state 
Medicaid program budgets.
• The projected budget impact of elafibranor and obeticholic acid highlights the need for 
innovative cost-containment strategies.
• Proactive pipeline monitoring and high-level budget impact modeling may assist state 
Medicaid programs in preparing for high-cost specialty medications that are likely to  
have significant cost implications.
FUTURE STUDIES
Continuous review and adjustment to assumptions made in this budget impact model are 
necessary as more clinical and economic data become available.
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INTRODUCTION
• NASH is a type of nonalcoholic fatty liver disease (NAFLD) that affects approximately  
15 million adults in the U.S.1,2
• Although largely asymptomatic, NASH can progress to cirrhosis, liver failure, and liver 
cancer, and is projected to become the most common indication for liver transplantation 
between 2020 and 2025.1,2
• There are no Food and Drug Administration (FDA)-approved therapies for NASH. The 
American Association for the Study of Liver Diseases (AASLD) recommends pioglitazone 
and vitamin E as options for select patients.1
• Several agents are currently in development for NASH, of which obeticholic acid and 
elafibranor are being tested in Phase III registration trials.3,4
• Given limited treatment options for NASH, the clinical interest in using novel therapies 
may be great once they become available.1
• A budget impact model may provide valuable insight to health insurers on the financial 
consequences of adopting novel therapies.
• A budget impact model was created to forecast the clinical and economic impact of  
two emerging investigational agents, elafibranor and obeticholic acid.
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Figure 1: 
Projected Pharmacy Budget Impact in Year One
NASH is associated with significant morbidity and mortality and if left untreated,  
may progress to liver transplantation.1
Based on available peer-reviewed literature, elafibranor and obeticholic acid may  
offer clinical advantages over currently available non-FDA approved therapies.2-5
Despite the treatment advancements these agents may offer, only ~20% of  
patients responded to therapy in clinical trials.3,4
The FDA-approval of elafibranor and obeticholic acid for NASH may  
present opportunities for innovative cost-containment strategies.
• Supplemental rebate: Selection of a preferred NASH agent
• Value-based contracts: Payment contingent on agreed-upon clinical outcomes
• Adherence monitoring: Promotion of appropriate medication use
Plan-specific projections may be made by utilizing medical claims data to  
determine the exact prevalence of NASH within the plan membership.
100,000
Covered Lives
3,500-5,000 
Patients with NASH
175-250 
Patients diagnosed/ 
may require treatment
If all diagnosed patients treated 
(n=175 to 250):
$13 to $18.6 million  
per year
If low [10%] uptake  
(n=18 to 25):
$1.3 to $1.9 million  
per year
Table 1: 
Evaluation of Elafibranor 
and Obeticholic Acid1-6
